Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose folinic acid versus placebo in young children with autism spectrum disorder
MOH_2026-05-04_015802Phase 2Recruiting
- Sponsor
- Shaare Zedek Medical Center
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing High-dose folinic acid then folinic acid dose-randomization with Placebo then folinic acid dose-randomization (2 arms). Primary endpoint: Change in Aberrant Behavior Checklist Irritability subscale. Started Apr 2026; status: recruiting.
02
Drugs
folinic acid
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on MOH_2026-05-04_015802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-04_015802.